0001178913-26-000185.txt : 20260225 0001178913-26-000185.hdr.sgml : 20260225 20260121130015 ACCESSION NUMBER: 0001178913-26-000185 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20260121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRINITY BIOTECH PLC CENTRAL INDEX KEY: 0000888721 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: IDA BUSINESS PARK STREET 2: BRAY CITY: WICKLOW PROVINCE COUNTRY: L2 BUSINESS PHONE: 01135312955111 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: IDA BUSINESS PARK STREET 2: BRAY CITY: WICKLOW PROVINCE COUNTRY: L2 CORRESP 1 filename1.htm

TRINITY BIOTECH PLC
 
January 21, 2026
 
VIA EDGAR
 
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549

Attention: Tim Buchmiller

 
Re: Trinity Biotech plc
Registration Statement on Form F-1
File No. 333- 292753
 
 
To Mr. Buchmiller:
 
The undersigned, on behalf of Trinity Biotech plc (“Trinity”), issuer of the securities covered by the above-referenced Registration Statement, hereby respectfully requests that the above-referenced Registration Statement be declared effective by the Securities and Exchange Commission at 4:00 p.m. Eastern Time on Friday, January 23, 2026, or as soon thereafter as possible.
 
Please contact Steven Glusband (212-238-8605, glusband@clm.com) or Mary Brown (212-238-8765, mbrown@clm.com) of Carter Ledyard & Milburn LLP with any questions you may have concerning this request.
 
 
Very truly yours,

/s/ Paul Murphy
Paul Murphy
Chief Financial Officer